Target intelligence / Profile preview

DNA gyrase subunit A (GyrA) (GyrA)

Target
GyrA
Molecular classification
Enzyme, Type II topoisomerase
01

Overview

DNA gyrase subunit A (GyrA) is a critical enzyme in Pseudomonas aeruginosa that belongs to the type II topoisomerase family [10]. It functions as a heterotetramer (A2B2) with subunit B to introduce negative supercoils into double-stranded DNA, a process essential for relieving torsional strain during DNA replication, transcription, and repair [10, 12]. GyrA specifically mediates the breakage and rejoining of DNA strands [6, 7]. In clinical practice, GyrA is the primary target for fluoroquinolone antibiotics such as ciprofloxacin and levofloxacin, which stabilize the enzyme-DNA cleavage complex and cause lethal double-strand breaks [1, 7]. However, P. aeruginosa frequently develops resistance through point mutations in the quinolone resistance-determining region (QRDR) of the gyrA gene, most commonly at positions Thr-83 and Asp-87 [1, 2, 3]. These mutations reduce the binding affinity of the drugs, posing a significant challenge in treating infections, particularly in immunocompromised patients or those with cystic fibrosis [1, 14].

Other names
DNA gyrase subunit AGyrADNA topoisomerase II subunit APA3168
02

Mechanism of action

Inhibition of DNA gyrase activity by binding to the GyrA protein/enzyme-DNA complex, preventing re-ligation of cleaved DNA strands, leading to double-strand DNA breaks and inhibition of bacterial DNA replication [1, 6, 7].

03

Biological functions

DNA replicationDNA transcriptionDNA supercoilingDNA repairDNA recombination
04

Disease associations

Infection
05

Safety considerations

Development of antibiotic resistance [1, 6]Cross-resistance among fluoroquinolones [2, 5]Therapeutic failure in multi-drug resistant strains [5, 6]
06

Interacting drugs

Ciprofloxacin

9 more in the full profile.

07

Biomarkers

gyrA gene mutations (e.g., Thr-83 to Ile, Asp-87 to Asn/Gly/His/Tyr) [1, 2, 3, 5, 14]

Beyond the preview

Go deeper on DNA gyrase subunit A (GyrA) (GyrA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNA gyrase subunit A (GyrA) (GyrA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call